Nerlynx

Chemical Nameneratinib maleate
Dosage FormTablet (oral; 40 mg)
Drug ClassKinase inhibitors
SystemFemale reproductive
CompanyPuma Biotech
Approval Year2017

Indication

  • As a single agent, for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.
  • In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.
Last updated on 10/14/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Nerlynx (neratinib maleate) Prescribing Information 2020Puma Biotechnology, Inc., Los Angeles, CA